GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Business Wire (Tue, 1-Sep 6:55 AM ET)
These ten healthcare stocks posted the biggest gains over the past month
Seeking Alpha News (Fri, 28-Aug 7:54 AM ET)
Business Wire (Mon, 24-Aug 8:30 AM ET)
Business Wire (Tue, 11-Aug 8:30 AM ET)
GeneDx to Participate in Upcoming Investor Conferences
Business Wire (Thu, 6-Aug 4:05 PM ET)
Market Chameleon (Tue, 4-Aug 3:08 AM ET)
GeneDx Reports Second Quarter 2026 Financial Results
Business Wire (Mon, 3-Aug 4:05 PM ET)
Business Wire (Mon, 3-Aug 11:51 AM ET)
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law
Globe Newswire (Mon, 3-Aug 9:53 AM ET)
PRNewswire (Mon, 3-Aug 2:54 AM ET)
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.
As of September 1, 2026, WGS stock price was flat at $84.81 with 335,967 million shares trading.
WGS has a beta of 0.62, meaning it tends to be less sensitive to market movements. WGS has a correlation of 0.01 to the broad based SPY ETF.
WGS has a market cap of $2.52 billion. This is considered a Mid Cap stock.
Last quarter Genedx Holdings Corp. - Class A reported $114 million in Revenue and $.01 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.20.
In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.
The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKE, ARKK, ARKG, IWM, VTI.
WGS has underperformed the market in the last year with a return of -34.5%, while SPY returned +19.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in WGS shares. However, WGS has outperformed the market in the last 3 month and 2 week periods, returning +63.1% and +9.6%, while SPY returned +1.0% and -1.4%, respectively. This indicates WGS has been having a stronger performance recently.
WGS support price is $81.29 and resistance is $88.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.